Jonathan Ownby, MD
Endocrinology, Diabetes & Metabolism · Atlanta, GANPI 1780887877
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $179,328 of the $291,282 with a category attached, or 61.6%. Corcept Therapeutics accounts for 79.2% of it on its own, with 59 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,670 payments — averaging $174.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$231K
- Merck$14K
- AbbVie$12K
- Lilly USA, LLC$6K
- Abbott$6K
- Novo Nordisk$3K
- plus $19K from 54 others
Across 117 payments — averaging $2372.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$199K
- Corcept Therapeutics$63K
- Amryt Pharma Holdings Ltd$11K
- Chiesi USA, Inc.$3K
- Aegerion Pharmaceuticals, Inc.$1K
What the payments were for
- Consulting fees$61,89021%
- Speaking & faculty fees$179,32862%
- Travel & lodging$17,9896%
- Food & beverage$31,97911%
- Education$950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$227,285
- STEGLATRO$13,580
- Synthroid$11,318
- FREESTYLE LIBRE 3$4,900
- HUMULIN$3,575
- Omnipod$1,405
- t-slim insulin pump$750
- iLet Bionic Pancreas$446
- Eversense$400
- CeQur Simplicity$381
- TRULICITY$322
- MYCAPSSA$300
- UNITY DIABETES MANAGEMENT SYSTEM$152
- RECORLEV$123
- GVOKE HYPOPEN$113
How this compares
$291,282 in reported general payments places this provider in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 45 | $1,585,818 |
| OzempicSemaglutide | 277 | $469,679 |
| FarxigaDapagliflozin Propanediol | 196 | $202,872 |
| MounjaroTirzepatide | 131 | $187,623 |
| JardianceEmpagliflozin | 88 | $107,175 |
| JanuviaSitagliptin Phosphate | 90 | $81,015 |
| TrulicityDulaglutide | 54 | $66,664 |
| RybelsusSemaglutide | 31 | $65,127 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 46 | $61,206 |
| Tresiba Flextouch U-100Insulin Degludec | 70 | $48,627 |
| JanumetSitagliptin Phos/Metformin Hcl | 40 | $42,433 |
| Xigduo XrDapaglifloz Propaned/Metformin | 45 | $38,577 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 28 | $37,639 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $36,691 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $24,670 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $230,774 | $1,585,81845 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $2,677 | $577,459363 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $6,497 | $265,460233 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $763 | $210,486208 claims |
| MerckJanuvia, Janumet, Janumet Xr | $14,193 | $161,088158 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $921 | $124,867114 claims |
| Johnson & JohnsonInvokana | $186 | $23,04214 claims |
| AbbVieSynthroid | $12,068 | $10,768101 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $706 | $3,067255 claims |
| Sanofi-aventis U.S. LLCLantus | $1,474 | $1,74313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Atlanta
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Gulliermo UmpierrezAtlanta$63K
- Francisco PasquelAtlanta$40K
- Norman WelchAtlanta$25K
- Rachel DerrAtlanta$18K
- Kate WheelerAtlanta$17K
- John ZoraAtlanta$16K
- Ernest BeasleyAtlanta$14K
- Era ShahAtlanta$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.